
Oil prices face 12% weekly drop as Middle East risks persist
Key points
- Brent crude and West Texas Intermediate (WTI) were heading for weekly losses of approximately 12% following the US midterm elections.
- Brent traded at $99.42 per barrel and WTI at $91.242, recovering from Thursday's close after reports of fresh tanker attacks in the Strait of Hormuz.
- Hopes for reduced Middle East tensions have weakened oil prices, but continued threats to Gulf shipping are maintaining a risk premium.
Brent crude and West Texas Intermediate crude are heading for weekly declines of approximately 12% on November 6, 2026, as expectations of reduced Middle East tensions pressured oil prices.
Both benchmarks had fallen sharply since Monday following the US midterm elections, although reports of fresh tanker attacks in the Strait of Hormuz triggered a recovery from Thursday's closing levels.
Both benchmarks remained substantially lower for the week despite the recovery, as traders reassessed the geopolitical risk premium previously built into oil prices.
At least five vessel incidents were reported in the Persian Gulf since Sunday, including three additional tanker attacks reported by Iran on Thursday, while UK maritime security data indicated that attacks on commercial vessels remained near record levels.
Brent was trading at $99.42 per barrel and WTI at $91.242, with both benchmarks recovering from Thursday's close but remaining on course for weekly losses of approximately 12%.
The Strait of Hormuz remains a critical route for global oil shipments, making security disruptions in the Persian Gulf an important factor in international crude supply and pricing.
Oil market expectations now depend heavily on developments in US-Iran relations, the security of commercial shipping and the possibility of further military escalation, which could reverse the recent decline in crude prices.
Frequently asked questions
More from United States
VEON acquires 33.75% stake in JungoTV portfolio
Palo Alto Networks eyes $500 million Clutch Security acquisition
Ultragenyx secures UK review for Sanfilippo gene therapy
Ziff Davis reports $289.3 million Q3 revenue
Suzano reports record R$16.5 billion Q3 revenue after Arbex consolidation
J&J wins FDA approval for 42% response cancer drug

